title: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.
abstract: The Cancer and Leukemia Group B (CALGB) has been conducting a prospective cytogenetic companion study (CALGB 8461) to all CALGB treatment protocols for newly diagnosed adults with acute lymphoblastic leukemia (ALL). These protocols underwent a significant change in 1988 when a new intensive chemotherapy program was introduced (CALGB 8811). We asked whether karyotype continued to represent a significant prognostic factor in adult ALL patients after the change. A total of 256 patients had adequate pretreatment cytogenetic analyses: 67 before 1988 and 189 subsequently. The complete remission (CR) rate for the whole group was 80%. Patients with t(9;22), t(4;11), -7, or +8 had significantly lower probabilities of continuous CR and survival at 5 years (.11 and.12) than patients with a normal karyotype (.38 and.37) and patients with miscellaneous cytogenetic abnormalities (.52 and.49; P <.001 for each comparison). When analyzed by treatment period, the CR rate before CALGB 8811 was 63%; subsequently, it was 86% (P <.001). Patients with cytogenetic abnormalities other than t(9;22), t(4;11), -7, or +8 had better CR rates, disease-free survival (DFS), and survivals (P =.001, P =.04, and P =.004, respectively) after the change to the more intensive chemotherapy regimens. Patients with normal cytogenetics had improved CR rate but no improved DFS or survival, whereas no significant benefit for patients with t(9;22), t(4;11), -7, or +8 was seen. In a multivariate analysis, karyotype retained its prognostic significance for DFS but not for survival; it remained the most important factor for DFS. We conclude that cytogenetic analysis at diagnosis should be used to guide treatment decisions in adults with ALL.
authors.affiliation: Roswell Park Cancer Institute, Buffalo, NY, USA. wetzler@SC3101.med.buffalo.edu
authors.forename: M
authors.initials: M
authors.lastname: Wetzler
authors.forename: R K
authors.initials: RK
authors.lastname: Dodge
authors.forename: K
authors.initials: K
authors.lastname: Mrózek
authors.forename: A J
authors.initials: AJ
authors.lastname: Carroll
authors.forename: R
authors.initials: R
authors.lastname: Tantravahi
authors.forename: A W
authors.initials: AW
authors.lastname: Block
authors.forename: M J
authors.initials: MJ
authors.lastname: Pettenati
authors.forename: M M
authors.initials: MM
authors.lastname: Le Beau
authors.forename: S R
authors.initials: SR
authors.lastname: Frankel
authors.forename: C C
authors.initials: CC
authors.lastname: Stewart
authors.forename: T P
authors.initials: TP
authors.lastname: Szatrowski
authors.forename: C A
authors.initials: CA
authors.lastname: Schiffer
authors.forename: R A
authors.initials: RA
authors.lastname: Larson
authors.forename: C D
authors.initials: CD
authors.lastname: Bloomfield
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D018572:Disease-Free Survival; D005819:Genetic Markers; D006801:Humans; D007621:Karyotyping; D015999:Multivariate Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D005819:Genetic Markers